Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. carries a market capitalization of 3.53B, placing it among publicly traded companies globally. Its enterprise value stands at 3.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.53B |
| Enterprise Value | 3.03B |
Share Statistics
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. currently has 327.30M shares outstanding.
| Shares Outstanding | 327.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 12.76. The price-to-sales ratio is 3.89, and the price-to-book ratio stands at 2.80.
| PE Ratio | 12.76 |
| PS Ratio | 3.89 |
| PB Ratio | 2.80 |
| P/TBV Ratio | 2.46 |
| P/FCF Ratio | 140.59 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang Cheng Yi Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 16.26 and an EV/FCF ratio of 108.62. The EV/Sales ratio of 3.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.26 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.91 |
| EV / EBITDA | 16.26 |
| EV / EBIT | 16.26 |
| EV / FCF | 108.62 |
Financial Position
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.10, indicating elevated leverage, while an interest coverage ratio of 26.44 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.53 |
| Quick Ratio | 0.78 |
| Debt / Equity | 16.10 |
| Debt / EBITDA | 1.11 |
| Interest Coverage | 26.44 |
Financial Efficiency
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. posts a return on equity of 23.44 and a return on invested capital of 10.91.
| Return on Equity (ROE) | 23.44 |
| Return on Assets (ROA) | 13.55 |
| Return on Invested Capital (ROIC) | 10.91 |
| Return on Capital Employed (ROCE) | 18.42 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.04 |
Taxes
Over the trailing twelve months, Zhejiang Cheng Yi Pharmaceutical Co., Ltd. has paid 22.03M in income taxes, reflecting an effective tax rate of 8.47.
| Income Tax | 22.03M |
| Effective Tax Rate | 8.47 |
Stock Price Statistics
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.'s stock has gained approximately 6.6482% over the past 52 weeks. The 50-day moving average sits at 7.97, while the 200-day moving average is 8.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | 6.6482% |
| 50-Day Moving Average | 7.97 |
| 200-Day Moving Average | 8.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Cheng Yi Pharmaceutical Co., Ltd. generated 775.25M in revenue and converted that into 236.66M in net income, yielding earnings per share of 0.73. EBITDA reached 186.68M, while operating income came in at 186.68M.
| Revenue | 775.25M |
| Gross Profit | 539.47M |
| Operating Income | 186.68M |
| Pretax Income | 260.24M |
| Net Income | 236.66M |
| EBITDA | 186.68M |
| EBIT | 186.68M |
| Earnings Per Share (EPS) | 0.73 |
Balance Sheet
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. holds 198.67M in cash and equivalents against 207.79M in total debt, resulting in a net debt position of -23.82M. Total book value stands at 1.08B, with working capital of 134.17M providing operational flexibility.
| Cash & Cash Equivalents | 198.67M |
| Total Debt | 207.79M |
| Net Debt | -23.82M |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 3.30 |
| Working Capital | 134.17M |
Cash Flow
After subtracting -21.47M in capital expenditures, free cash flow totaled -21.47M - equivalent to -0.07 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -21.47M |
| Free Cash Flow | -21.47M |
| FCF Per Share | -0.07 |
Margins
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. operates with a gross margin of 69.59, reflecting its pricing power and cost economics. The operating margin of 24.08 and net profit margin of 30.53 provide insight into operational efficiency.
| Gross Margin | 69.59 |
| Operating Margin | 24.08 |
| Pretax Margin | 33.57 |
| Profit Margin | 30.53 |
| EBITDA Margin | 24.08 |
Dividends & Yields
The company's payout ratio of 36.12 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.26 |
| Dividend Yield | N/A |
| Payout Ratio | 36.12 |
| Shareholder Yield | 11.23 |
| FCF Yield | 0.71 |
Stock Splits
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.'s most recent stock split took place on June 26, 2026 with a 5:7 split ratio.
| Last Split Date | 6/26/2026 |
| Split Ratio | 5:7 |
Scores
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. posts an Altman Z-Score of 6.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.07 |